3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
4
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Prostatic Neoplasms, Castration-Resistant
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Carcinoma, Hepatocellular
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasm Metastasis
1
Mesothelioma
1
Liver Neoplasms
1
Lethal Congenital Contracture Syndrome 2
1
Fibromatosis, Gingival, 2
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Small Cell
1
Carcinoma, Renal Cell
1
Camurati-Engelmann Syndrome
1
Breast Neoplasms
1
Anus Neoplasms
1
Adenocarcinoma
1
Interventions
enzalutamide
1
abiraterone
1
Quality of Life
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Immunotherapy
1
Drug Therapy
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Small Cell
×
enzalutamide
×
Dermatologic
×
Clear all
NCT05551117
2026-02-09
Tamarack
MacroGenics
Phase 2
Terminated
192 enrolled
20 charts